TipRanks
Manulife Financial Corp (MX:MFCN)
:MFCN
Mexico Market
EarningsQ2 2026 Earnings Report

Manulife Financial (MFCN) Q2 2026 Earnings Report

0 Followers

MX:MFCN Q2 2026 EPS Results

Actual EPS$13.35
Consensus EPS$13.23
Beat/MissBeat by +$0.12
One Year Ago EPS$11.64

MX:MFCN Q2 2026 Revenue Results

Actual Revenue$244.94B
Expected Revenue―
Beat/Miss―
YoY Revenue Growth+28.19%

Earnings Announcement Details

QuarterQ2 2026
Date08/05/2026
TimeAfter Close
Conference CallWednesday, August 5, 2026
MX:MFCN Upcoming Earnings
Manulife Financial's next earnings date is estimated for November 4, 2026, based on past reporting schedules.

Q2 2026 Earnings Call Audio

MX:MFCN Q2 2026 Earnings Call
0:00 / 0:00

Q2 2026 Earnings Slide Deck

Q2 2026 Earnings Call Summary

Q2 2026
Earnings Call Date:Aug 05, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call highlighted multiple strong operating and financial results — double-digit APE growth across segments, meaningful improvements in new business metrics and core EPS, robust capital ratios (LICAT 136%) and strategic execution including an innovative LTC biometric risk transfer and AI leadership. Headwinds include unfavorable insurance experience in Canada and some U.S. life spread/ALDA pressure, targeted outflows in parts of Global WAM, and elevated central expenses. Management presented these challenges as manageable with mitigating actions (claims management, repricing ability, continued capital generation and targeted investments). Overall, the positives around growth, profitability, capital strength and risk-reduction transactions materially outweigh the contained negatives.
Company Guidance
The company reiterated its medium‑term/2027 guidance and capital priorities: an 18%+ core ROE ambition (Q2 core ROE 16.3%, +130 bps YoY), a 2.5% ongoing share‑buyback program, and on‑track 2027 remittances, supported by strong capital and leverage metrics (LICAT 136%, ≈$26B excess of supervisory target; financial leverage 22.2% vs. 25% medium‑term target). Management expects Canada insurance experience to trend to neutral by year‑end, corporate results to be a loss of $300–$400M (likely toward the high end), and an expense‑efficiency medium‑term target below 45% (44.5%); operating and growth metrics cited include APE sales +21% YoY (Asia +21%, Hong Kong +37%, Canada +23%, U.S. +12%), new business CSM +16% YoY, CSM balance +20%, Global WAM net inflows $0.4B, core EPS +16% (core earnings +12% YoY; Asia core earnings +21%; Global WAM core earnings +9%), adjusted book value per share $41.12 (+15% YoY), core EBITDA margin 31.2% (+110 bps), and details on the LTC transaction ($3.2B of reserves at 80% quota share, ~−5% IFRS cede / ~6–7% NAIC cede, CAD 30M foregone core earnings in year 1), which reduces LTC morbidity risk by 24% while current LTC claim savings exceed 6% and the retained block is expected to start generating capital over the next 5–10 years.
Strong APE Sales Growth Across Segments
Total APE sales grew 21% year-over-year with double-digit growth across all insurance segments: Asia +21%, Canada +23%, U.S. +12%. APE sales per active agent increased over 30% YoY.
Improved New Business Economics and CSM
New business CSM increased 16% YoY and overall CSM balance grew 20%, supporting future earnings generation and demonstrating improvement in value metrics.
Profitability and EPS Growth
Core EPS grew 16% YoY, driven by 12% growth in core earnings and share buybacks; adjusted book value per share rose 15% YoY to $41.12.
Asia and Global WAM Outperformance
Asia core earnings increased 21% YoY to a record level; Global WAM generated 10% pretax earnings growth, returned to net inflows of $0.4 billion supported by record gross flows, and expanded core EBITDA margin to 31.2% (up 110 bps YoY).
Capital and Balance Sheet Strength
LICAT ratio of 136% (about $26 billion in excess of supervisory target) and financial leverage at 22.2% (below 25% medium-term target) provided flexibility; returned $5.3 billion of capital to shareholders over the past 12 months and $1.4 billion in the quarter.
Long-Term Care (LTC) Risk Reduction Transaction
Completed a biometric risk-only LTC reinsurance with Munich Re: full transfer of biometric risk on $3.2 billion of reserves at an 80% quota share, reducing LTC morbidity risk by 24% (inclusive of prior transactions); transaction priced with a modest ~5% negative ceding commission (IFRS) and ~6–7% on NAIC basis; foregone core earnings ~CAD 30 million in year one.
Operational and Innovation Achievements
Recognized as #1 life insurer for AI maturity (Evident) and Model Insurer for Data, Analytics & AI (Celent); launched enterprise AI platform and Agentic AI solutions; expanded product offerings (high net worth insurance solutions, ETF offerings, VUL enhancements) and scaled agency training and capability programs (Manulife Business Academy).

MX:MFCN Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Nov 04, 2026
2026 (Q3)
14.61 / -
14.208―
2026 (Q2)
13.23 / 13.35
11.63614.74% (+1.71)
2026 (Q1)
13.42 / 12.98
12.1267.07% (+0.86)
2025 (Q4)
13.04 / 13.72
12.6168.74% (+1.10)
2025 (Q3)
12.73 / 14.21
12.24816.00% (+1.96)
2025 (Q2)
11.86 / 11.64
11.1464.40% (+0.49)
2025 (Q1)
11.98 / 12.13
11.5135.32% (+0.61)
2024 (Q4)
11.57 / 12.62
11.26811.96% (+1.35)
2024 (Q3)
11.48 / 12.25
11.2688.70% (+0.98)
2024 (Q2)
10.79 / 11.15
10.1669.64% (+0.98)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed